BioNTech doubles down on ADC partner MediLink in new $1.8B biobucks pact
As BioNTech’s pipeline tilts back toward oncology, the German biotech is once again tapping a young Chinese partner in a bid for the next generation …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
